|
VRK2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.06029999949564E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.380099999999E-05 |
| Normal-vs-Stage2 |
3.84649999962683E-07 |
| Normal-vs-Stage3 |
3.25270000045563E-07 |
| Normal-vs-Stage4 |
1.8665099999926E-05 |
| Stage1-vs-Stage2 |
1.222360E-02 |
| Stage1-vs-Stage3 |
7.378400E-02 |
| Stage1-vs-Stage4 |
3.360600E-01 |
| Stage2-vs-Stage3 |
2.727800E-01 |
| Stage2-vs-Stage4 |
1.293790E-01 |
| Stage3-vs-Stage4 |
5.332200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.78549999960443E-07 |
| Normal-vs-AfricanAmerican |
2.217900E-03 |
| Normal-vs-Asian |
1.600540E-03 |
| Caucasian-vs-AfricanAmerican |
9.785600E-01 |
| Caucasian-vs-Asian |
3.076000E-01 |
| AfricanAmerican-vs-Asian |
4.777400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.3041000002676E-07 |
| Normal-vs-Female |
1.0862999999528E-06 |
| Male-vs-Female |
4.556600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.242430E-04 |
| Normal-vs-Age(41-60Yrs) |
7.86910000050156E-07 |
| Normal-vs-Age(61-80Yrs) |
9.28560000001966E-08 |
| Normal-vs-Age(81-100Yrs) |
1.738110E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.011370E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.862160E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.160600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.497400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.181400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.000200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.579400E-01 |
| Classical-VS-Follicular |
6.316100E-03 |
| Classical-VS-Other |
3.624400E-01 |
| Classical-VS-Normal |
2.08139999999801E-05 |
| Tall-VS-Follicular |
1.318590E-01 |
| Tall-VS-Other |
5.304600E-01 |
| Tall-VS-Normal |
1.220140E-03 |
| Follicular-VS-Other |
8.497200E-01 |
| Follicular-VS-Normal |
1.10239999995265E-06 |
| Other-VS-Normal |
2.114300E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.69040000278054E-08 |
| Normal-vs-N1 |
3.28689999995468E-06 |
| N0-vs-N1 |
7.889400E-01 |
|
|
